Brain Volume Changes in Early Alzheimer's Disease

Brain Volume Changes in Early Alzheimer's Disease

Overview

A landmark study using intravoxel incoherent motion (IVIM) diffusion MRI has challenged the prevailing assumption that brain volume increases in early Alzheimer's disease (AD) result from intracellular fluid accumulation. The research, conducted on 297 cognitively unimpaired individuals from the ALFA study cohort, reveals that these volume changes are instead driven by glial remodeling and microstructural changes, offering new insights into the earliest stages of AD pathology.

Brain Volume Changes in Early Alzheimer's Disease

Overview

A landmark study using intravoxel incoherent motion (IVIM) diffusion MRI has challenged the prevailing assumption that brain volume increases in early Alzheimer's disease (AD) result from intracellular fluid accumulation. The research, conducted on 297 cognitively unimpaired individuals from the ALFA study cohort, reveals that these volume changes are instead driven by glial remodeling and microstructural changes, offering new insights into the earliest stages of AD pathology.

Key Finding: Not Intracellular Fluid

Contrary to expectations, the study found no association between diffusion parameters and amyloid biomarkers (both PET and CSF measures). This suggests that the brain volume increases observed in cognitively unimpaired amyloid-positive individuals are not driven by intracellular water accumulation as previously hypothesized.

Instead, the findings indicate that these volume changes reflect:

• Glial remodelling — changes in glial cell morphology and density
• Microstructural alterations — changes in tissue architecture at the cellular level
• Increased cellular complexity — rather than fluid accumulation

The IVIM-MRI Methodology

What is IVIM?

Intravoxel incoherent motion (IVIM) diffusion MRI is an advanced neuroimaging technique that separates perfusion effects from true diffusion, providing insight into the microstructural properties of brain tissue without requiring contrast agents.

Three-Compartment Model

The researchers developed a sophisticated three-compartment diffusion MRI model with four key parameters:

This model allows researchers to distinguish between:

• True cellular changes (tracked by slow diffusion)
• Vascular/perfusion effects (tracked by perfusion parameters)

Why IVIM Matters for AD Research

Traditional MRI can only measure total brain volume, which increases in early AD before later declining. By decomposing volume changes into their biophysical components, IVIM provides a mechanistic window into what drives these early volume increases.

Study Details

Cohort

• Participants: 297 cognitively unimpaired late middle-aged adults
• Amyloid prevalence: 35% showed evidence of amyloid deposition
• Source: ALFA (Alzheimer's and FAbries disease) study cohort

Key Associations

No Association with Amyloid

• Diffusion parameters showed no significant associations with:
• Amyloid PET measures
• CSF amyloid biomarkers

Strong Associations with Neuroinflammation and Neurodegeneration

• Neuroinflammation — particularly in frontoparietal and cingulate regions
• Neurodegeneration — in the same brain regions

Regional Findings

In amyloid-related grey matter regions where volume increases were linked to amyloid:

• Volume negatively correlated with slow diffusion coefficient (P=0.001)
• Volume negatively correlated with perfusion fraction (P=0.036)
• Volume negatively correlated with mean diffusivity (P=0.047)

Implications for Understanding AD Pathogenesis

Reframing Early AD Changes

This finding challenges a fundamental assumption about early AD pathophysiology:

| Previous Hypothesis | New Understanding |
|---------------------|-------------------|
| Intracellular fluid accumulation drives early brain volume increases | Glial remodeling and microstructural changes drive early brain volume increases |

Clinical Implications

Relationship to Other Biomarkers

The strong associations between diffusion parameters and neuroinflammation/neurodegeneration biomarkers (even in the absence of amyloid correlations) suggest that:

• Neuroinflammatory processes may be detectable before amyloid-driven volume changes manifest
• Glial activation represents an early and potentially targetable process in AD
• Microstructural changes may precede or accompany amyloid deposition without direct correlation

Cross-References

Related Mechanisms

• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade) — amyloid deposition and its downstream effects
• [Neuroinflammation in Alzheimer's Disease](/mechanisms/ad-neuroinflammation-microglia-pathway) — microglial activation and inflammatory responses
• [Astrocyte Reactivity in Neurodegeneration](/mechanisms/astrocyte-reactivity) — astrocyte morphological changes
• [Cellular Senescence in Alzheimer's Disease](/mechanisms/cellular-senescence-alzheimers) — age-related glial changes

Related Biomarkers

• [Neuroinflammation Biomarkers Overview](/biomarkers/neuroinflammation-biomarkers-overview) — biomarkers of inflammatory processes
• [CSF Biomarkers](/technologies/cerebrospinal-fluid-analysis) — cerebrospinal fluid analysis in AD

Related Cell Types

• [Microglia](/cell-types/microglia) — brain immune cells central to neuroinflammation
• [Astrocytes](/cell-types/astrocytes) — supporting cells that undergo remodeling

Outstanding Questions

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [TREM2-Dependent Microglial Senescence Transition](/hypothesis/h-61196ade) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: TREM2
• [Targeted Butyrate Supplementation for Microglial Phenotype Modulation](/hypothesis/h-3d545f4e) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: GPR109A
• [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
• [Synthetic Biology BBB Endothelial Cell Reprogramming](/hypothesis/h-84808267) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: TFR1, LRP1, CAV1, ABCB1
• [Cell-Type Specific TREM2 Upregulation in DAM Microglia](/hypothesis/h-seaad-51323624) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: TREM2
• [Age-Dependent Complement C4b Upregulation Drives Synaptic Vulnerability in Hippocampal CA1 Neurons](/hypothesis/h-2f43b42f) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: C4B
• [Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflammatory Priming](/hypothesis/h-f3fb3b91) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: TLR4

Related Analyses:

• [Gene expression changes in aging mouse brain predicting neurodegenerative vulnerability](/analysis/SDA-2026-04-02-gap-aging-mouse-brain-20260402) &#x1f504;
• [Gene expression changes in aging mouse brain predicting neurodegenerative vulnerability](/analysis/SDA-2026-04-02-gap-aging-mouse-brain-v2-20260402) &#x1f504;
• [Gene expression changes in aging mouse brain predicting neurodegenerative vulnerability](/analysis/SDA-2026-04-02-gap-aging-mouse-brain-v3-20260402) &#x1f504;
• [Gene expression changes in aging mouse brain predicting neurodegenerative vulnerability](/analysis/SDA-2026-04-02-gap-aging-mouse-brain-v4-20260402) &#x1f504;
• [Gene expression changes in aging mouse brain predicting neurodegenerative vulnerability](/analysis/SDA-2026-04-02-gap-aging-mouse-brain-v5-20260402) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving Brain Volume Changes in Early Alzheimer's Disease discovered through SciDEX knowledge graph analysis: